NCT07490769RecruitingPhase 3
Levetiracetam Three Times Daily in Epilepsy
Evaluating Efficacy and Tolerability of Three Times Daily Levetiracetam in Epilepsy Patients
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
The purpose of this clinical trial is to evaluate the efficacy and tolerability of Levetiracetam administered three times daily in patients with epilepsy. The primary objective is to investigate whether orally administered Levetiracetam three times daily dosing is superior in seizure-free days compared to standard twice-daily dosing in patients with epilepsy. Key questions include: * Does LEV improve seizure control, as measured by seizure-free days? * What adverse events or safety concerns are observed with LEV treatment? Participants will receive Levetiracetam administered three times daily during the treatment phase. The study will use a self-matched, pre-post design in which each participant serves as their own control. Baseline seizure activity and safety data will be collected prior to LEV initiation and compared with data obtained during the treatment period. Participants will attend scheduled clinic visits for efficacy and safety evaluations and will maintain a daily diary to record seizure frequency and any treatment-related events.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 11 Mar 2026
- Start date
- 1 Oct 2025
- Primary completion date
- 30 Dec 2028
- Lead sponsor
- Waad Alkathiri
- Diseases
- Epilepsy
- NCT number
- NCT07490769
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 120
- From 1 Oct 2025 to the primary completion date, 30 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received Levetiracetam intravenous within the last 24hr.
- Co-administered with other antiepileptic drugs
- Received other antiepileptic drugs in the last two weeks.
Other illness
- Renal impairment (Crcl \< 30) or Acute kidney injury
Age
- Younger than Aged 18 years
Other
- Pregnant women.
Who the study is looking for
- Aged 18 years or older.
- diagnosed with uncontrolled Epilepsy of any type (defined as one or more unprovoked seizures in the last 6 months)
- On Levetiracetam monotherapy
- Participants must have a documented history of Levetiracetam use for at least 12 months prior to enrollment.
- on Levetiracetam high dose (1.5 - 3 g daily)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| King Saud University Coordinator of this site? Confirm its status | Riyadh | Saudi Arabia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.